Search clinical trials for: immune Checkpoint Inhibitors

Total 108262 results

Institut für Klinische Krebsforschung IKF GmbH...
Medizinische Hochschule Hannover, Germany, Prof. Dr. Arndt Vogel; MSD Sharp...

Recruiting

Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer (TRAP-BTC)

Biliary Tract Cancer | HER2 Gene Mutation

Germany
Shanghai Chest Hospital

Recruiting

Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer

Esophageal Squamous Cell Carcinoma | Unresectable Locally Advanced Esophageal Cancer

China
Soonchunhyang University Hospital

Not yet recruiting

A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy (DICI_PC)

Pancreas Cancer
Qilu Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing Pharmacokinetic and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy Adults

Tumor

China
Xencor, Inc.

Recruiting

Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

Nonsquamous Non-small Cell Lung Cancer

United States
Astellas Pharma Global Development, Inc.

Recruiting

A Study of ASP1012 in Adults With Solid Tumors

Solid Tumor

United States
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Non-small Cell Lung Cancer (NSCLC)

China, Turkey, Australia, United States, Chile, Taiwan, Denmark, France, Spain, Argentina, Italy, Netherlands, Thailand, Korea, Republic of, Czechia, Portugal
Bristol-Myers Squibb

Recruiting

An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany (NENI)

Resectable Non-small Cell Lung Cancer

Germany
Melanoma and Skin Cancer Trials Limited

Not yet recruiting

Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases (BETTER)

Melanoma Brain Metastases
Northwestern University
National Cancer Institute (NCI)

Recruiting

Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma

Classic Hodgkin Lymphoma

United States
Revolution Medicines, Inc.

Recruiting

Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC

Non-Small Cell Lung Cancer, NSCLC | KRAS, NRAS, HRAS-mutated NSCLC | KRAS G12C-mutated Solid Tumors, Lung Cancer | Lung Cancer Stage IV, Advanced Solid Tumor, Cancer

United States
National Cancer Institute (NCI)

Not yet recruiting

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer

Squamous Cell Carcinoma of the Penis | Renal Medullary Carcinoma | Squamous Cell Carcinoma of the Bladder | Small Cell Carcinoma of the Bladder | Small Cell Carcinoma of the Urinary Tract | Squamous Cell Carcinoma of the Urinary Tract | Primary Adenocarcinoma of the Bladder | Primary Adenocarcinoma...

United States
National Cancer Institute (NCI)

Not yet recruiting

Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

Stage II Squamous Cell Carcinoma of the Head and Neck | Stage III Squamous Cell Carcinoma of the Head and Neck | Stage IV Squamous Cell Carcinoma of the Head and Neck

United States
National Cancer Centre, Singapore
Merck Sharp & Dohme LLC; National Medical Research Council (NMRC), Singapore

Not yet recruiting

Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma (POLAR)

Refractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma

Singapore
University of Pennsylvania

Not yet recruiting

CD40 Agonist and PD-1 Inhibitor in HNSCC

Head and Neck Squamous Cell Carcinoma
Sandoz

Recruiting

A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Metastatic NSCLC

Georgia
Fudan University

Recruiting

A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer (G/GEJ cancer)

Gastric Cancer/Adenocarcinoma of Esophagogastric Junction

China
Shanghai Henlius Biotech

Recruiting

A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects

Healthy Male Volunteers

China
Queensland Institute of Medical Research
Merck Sharp & Dohme LLC; Royal Brisbane and Women's Hospital; Princess Alexandra... and other collaborators

Recruiting

T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma (TCaP)

Glioblastoma Multiforme | Astrocytoma, Grade IV

Australia
Fudan University

Recruiting

PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

Nasopharyngeal Carcinoma

China
Precigen, Inc
National Cancer Institute (NCI)

Recruiting

PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

Cervical Cancer | HPV-Related Malignancy | Recurrent Cervical Carcinoma | HPV-Related Carcinoma | Metastatic Cervical Cancer

United States
Istituto Oncologico Veneto IRCCS
MSD Italia S.r.l.

Not yet recruiting

Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) (CHIMERA)

Pleural Mesothelioma

Italy
Sandoz

Recruiting

A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma

Melanoma

Romania
Boehringer Ingelheim

Recruiting

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Lung Cancer, Non-squamous, Non-small Cell

Australia, Korea, Republic of, China, Japan, United States, Hong Kong, Singapore, Taiwan
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer (MONAMI)

MSI | dMMR Colorectal Cancer

France
Melanoma Institute Australia
Bristol-Myers Squibb

Recruiting

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Merkel Cell Carcinoma

Australia
BioNTech SE
Genmab

Recruiting

Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors

Advanced Malignant Solid Tumor

United States, United Kingdom
Massachusetts General Hospital
Foundation Medicine

Recruiting

Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation

Melanoma | Non-small Cell Lung Cancer

United States
First Affiliated Hospital, Sun Yat-Sen University

Not yet recruiting

Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy

Papillary Renal Cell Carcinoma
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function

Sickle Cell Disease

United States
Peking Union Medical College Hospital

Not yet recruiting

A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.

Non Small Cell Lung Cancer | Immune Checkpoint Inhibitor | EGFR Exon 21 Mutation

China
Fujian Cancer Hospital

Not yet recruiting

Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer

Cervical Cancer
Vanderbilt-Ingram Cancer Center
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer

Limited Stage Lung Small Cell Carcinoma | Stage III Lung Cancer | Stage I Lung Cancer | Stage II Lung Cancer

United States
University of Leipzig
University of Kiel; University of Cologne; University of Jena; Technical University... and other collaborators

Not yet recruiting

European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] (ELOS)

Laryngeal Cancer | Squamous Cell Carcinoma of Head and Neck | Laryngeal Neoplasms | Squamous Cell Carcinoma of the Larynx | Hypopharyngeal Squamous Cell Carcinoma | Laryngeal Squamous Cell Carcinoma | Laryngectomy; Status | Squamous Cell Carcinoma of Larynx | Squamous Cell Carcinoma of the Larynx Stage... and other conditions
Dartmouth-Hitchcock Medical Center

Not yet recruiting

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Triple Negative Breast Cancer | Residual Disease
Qingdao Central Hospital

Recruiting

Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer

Metastatic Esophageal Squamous Cell Carcinoma

China
West China Second University Hospital

Recruiting

Cardiac Magnetic Resonance Monitoring of Immune Checkpoint Inhibitor-related Cardiotoxicity

Immune Checkpoint Inhibitors, Cardiotoxicity

China
West China Hospital

Not yet recruiting

Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC

NSCLC Associated With Leptomeningeal Metastases
Chang Gung Memorial Hospital

Recruiting

Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma (ProtonAB)

Hepatocellular Carcinoma Non-resectable

Taiwan
Memorial Sloan Kettering Cancer Center
Exelixis

Recruiting

A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain

Metastatic Renal Cell Carcinoma | Brain Metastases

United States
Amgen

Recruiting

A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Taiwan, Australia, United States, Japan, Korea, Republic of, Poland
Maria Sklodowska-Curie National Research Institute...
Immutep S.A.S.

Recruiting

Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial (EFTISARC-NEO)

Immunotherapy | Sarcoma,Soft Tissue | Radiation Therapy | Neoadjuvant

Poland
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer

Lung Cancer

United States
First Affiliated Hospital of Guangxi Medical University

Recruiting

Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer

Colonic Neoplasms | Neoadjuvant Therapy | Immune Checkpoint Inhibitors

China
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC; Genentech, Inc.

Recruiting

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

Esophageal Cancer | Gastric Adenocarcinoma | HER2 Gene Mutation

United States
Bayer

Recruiting

An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery (REFINE-IO)

Unresectable Hepatocellular Carcinoma

Greece, Spain, Brazil, China, Colombia, Italy, Saudi Arabia, Taiwan, Thailand, United States, Korea, Republic of, Argentina, France, Mexico, Turkey
Eli Lilly and Company
Loxo Oncology, Inc.

Recruiting

A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01)

Carcinoma, Non-Small-Cell Lung | Neoplasm Metastasis

United States, China, Taiwan, Belgium, Australia, Japan, United Kingdom, Spain, France, Germany, Austria, Korea, Republic of, Hungary, Switzerland, Mexico, Norway, Italy, Turkey, Greece, Portugal, Netherlands, India, Romania, Canada, De... and more
Erasmus Medical Center

Recruiting

Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response (NIVOPTIMIZE)

Melanoma

Netherlands
Servier Bio-Innovation LLC
Merck Sharp & Dohme LLC; Institut de Recherches Internationales Servier

Not yet recruiting

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

MSI-H/dMMR Gastroesophageal-junction Cancer | MSI-H/dMMR Gastric Cancer
Gustave Roussy, Cancer Campus, Grand Paris
Merck Sharp & Dohme LLC

Not yet recruiting

Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab (NeoSarc)

Cancer

France

Search clinical trials for: immune Checkpoint Inhibitors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations